Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancer Letters|January 18, 2018
Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinomaKaren C Galvin, Melissa J Conroy, Suzanne L Doyle, et al.Biomedicines|April 27, 2024
Analysing the Combined Effects of Radiotherapy and Chemokine Receptor 5 Antagonism: Complementary Approaches to Promote T Cell Function and Migration in Oesophageal AdenocarcinomaMaria Davern, Cillian O' Donovan, Noel E Donlon, et al.Translational Oncology|April 2, 2022
Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinomaMaria Davern, Noel E Donlon, Fiona O' Connell, et al.Journal of Cancer Research and Clinical Oncology|November 29, 2022
Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapyMaria Davern, Noel E Donlon, Fiona O'Connell, et al.Cancer Immunology, Immunotherapy : CII|June 16, 2022
Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patientsMaria Davern, Noel E Donlon, Fiona O'Connell, et al.Frontiers in Immunology|February 14, 2022
The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint InhibitionNoel E Donlon, Maria Davern, Andrew D Sheppard, et al.Frontiers in Immunology|July 30, 2019
Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal AdenocarcinomaAshanty M Melo, Aisling M O'Brien, James J Phelan, et al.Journal of Cancer Research and Clinical Oncology|February 15, 2023
Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cellsMaria Davern, Dara Bracken-Clarke, Noel E Donlon, et al.Journal of Cancer Research and Clinical Oncology|August 20, 2022
FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapyMaria Davern, Noel E Donlon, Andrew S Sheppard, et al.Pageof 4